Insmed Awarded $2.1 Million by Muscular Dystrophy Association
12 Décembre 2007 - 3:00PM
PR Newswire (US)
RICHMOND, Va., Dec. 12 /PRNewswire-FirstCall/ -- Insmed Inc.
(NASDAQ:INSM), today announced that it has been awarded a grant of
$2,087,325 from the Muscular Dystrophy Association (MDA). The grant
is expected to cover a substantial portion of the external costs
associated with Insmed's 24-week Phase 3 enabling trial in patients
with Myotonic Muscular Dystrophy (MMD). Insmed, a development stage
biopharmaceutical company with extensive expertise in biologics and
orphan drug development, decided to initiate the Phase 3 enabling
trial based on promising results from an ongoing open-label,
dose-escalation trial of IPLEX(TM) in MMD. To date, up to 70% of
patients have reported improvements in one or more of several
symptoms commonly associated with Myotonic Muscular Dystrophy.
Furthermore, patients undergoing a standardized 6 minute walk test,
a well accepted FDA endpoint for endurance, have significantly
improved their walking distance (p
Insmed (NASDAQ:INSM)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Insmed (NASDAQ:INSM)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024